利拉鲁肽治疗2型糖尿病合并肥胖患者的效果

Effect of Liraglutide in the Treatment of Type 2 Diabetes Mellitus Patients with Obesity

目的:探讨利拉鲁肽治疗2型糖尿病合并肥胖患者的效果。方法:选取2018年4月-2019年4月高州市人民医院收治的72例2型糖尿病合并肥胖患者,随机分为对照组与观察组,每组36例。对照组接受常规治疗,观察组接受利拉鲁肽治疗。比较两组血糖和血脂水平、肥胖相关指标及不良反应发生情况。结果:治疗后,观察组FPG、HbA1c、2 h PG水平均低于对照组(P<0.05)。治疗后,观察组LDL-C、HDL-C及TC水平均优于对照组(P<0.05)。治疗后,观察组体重指数(BMI)、腹围均低于对照组(P<0.05)。观察组不良反应发生率低于对照组(P<0.05)。结论:2型糖尿病合并肥胖患者应用利拉鲁肽治疗,可有效改善患者的血糖和血脂水平,降低患者的BMI,同时不会产生较严重的不良反应,值得推广应用。

Objective:To investigate the effect of Liraglutide in the treatment of type 2 diabetes mellitus with obesity.Method:A total of 72 patients with type 2 diabetes complicated with obesity admitted to the People’s Hospital of Gaozhou from April 2018 to April 2019 were randomly divided into control group and observation group,with 36 patients in each group.Control group received conventional treatment,observation group received Liraglutide treatment.The levels of blood glucose and lipid,obesity-related indexes and the incidence of adverse reactions were compared between the two groups.Result:After treatment,the levels of FPG,HbA1c and 2 h PG in observation group were lower than those in control group(P<0.05).After treatment,the levels of LDL-C,HDL-C and TC in observation group were better than those in control group(P<0.05).After treatment,body mass index(BMI)and abdominal circumference in the observation group were lower than those in the control group(P<0.05).The incidence of adverse reaction in observation group was lower than that in control group(P<0.05).Conclusion:Liraglutide can effectively improve blood glucose and lipid levels and reduce BMI in patients with type 2 diabetes complicated with obesity,without causing serious adverse reactions,which is worthy of popularization and application.